Spyre Therapeutics, Inc. (SYRE) Tops Q3 EPS by 62c

Spyre Therapeutics, Inc. (NASDAQ: SYRE) reported Q3 EPS of ($0.15), $0.62 better than the analyst estimate of ($0.77).

For earnings history and earnings-related data on Spyre Therapeutics, Inc. (SYRE) click here.

You May Also Be Interested In

• Mosaic (MOS), Others Lower Following Trump Post on Potash from Belarus
• RBC Capital Upgrades Telix Pharmaceuticals Ltd (TLX:AU) (TLX) to Outperform
• Super Micro Computer rises on AI server market optimism